WB
H
Endogenous
78
Rabbit
#Q96AY3
60681
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro425 of human FKBP10 protein. Antibodies are purified by peptide affinity chromatography.
Background
FK506-binding proteins (FKBPs) are a large family of conserved proteins characterized by the presence of one or more peptidyl-prolyl cis-trans isomerase (PPIase) domains. The founding member FKBP12 was originally identified as a non-covalent binding protein of FK506 and rapamycin, two widely used immunosuppressive drugs, and mediated their immunosuppressive activity. The FKBP12-FK506 complex specifically targets the Ca2+-dependent serine-threonine phosphatase calcineurin, and the FBKP12-rapamycin complex acts on mTOR (mammalian target of rapamycin). While both FK506 and rapamycin bind to the PPIase domain and inhibit PPIase activity of FKBP12, the inhibition of PPIase activity per se does not contribute to their immunosuppressive activity. Some members of the FKBP family also contain other functional domains or motifs. FKBPs have been reported to play roles in diverse processes such as protein folding, cellular signaling, and transcription, and have been implicated in several diseases (1-3).
FKBP10, also known as FKBP65 (65 kDa FK506-binding protein), has four tandem PPIase domains and is an endoplasmic reticulum (ER) resident protein, where it modulates the folding and trafficking of secretory proteins. FKBP10 plays an important role in collagen folding and secretion and its mutation is associated with osteogenesis imperfecta (4-6), and it is considered as a therapeutic target for idiopathic pulmonary fibrosis (IPF) (7,8). Recent reports suggest that FKBP10 may be a biomarker or therapeutic targets for several different cancers (9-11).
- Bonner, J.M. and Boulianne, G.L. (2017) Cell Signal 38, 97-105.
- Tong, M. and Jiang, Y. (2015) Curr Mol Pharmacol 9, 48-65.
- Ghartey-Kwansah, G. et al. (2018) BMC Dev Biol 18, 7.
- Ishikawa, Y. et al. (2017) J Biol Chem 292, 17216-17224.
- Li, S. et al. (2020) Front Genet 11, 984.
- Lietman, C.D. et al. (2017) J Bone Miner Res 32, 1354-1367.
- Staab-Weijnitz, C.A. et al. (2015) Am J Respir Crit Care Med 192, 455-67.
- Knüppel, L. et al. (2018) Respir Res 19, 67.
- Ge, Y. et al. (2017) Urol Int 98, 169-176.
- Liang, L. et al. (2019) Oncol Rep 42, 615-628.
- Gong, L.B. et al. (2020) Onco Targets Ther 13, 7399-7409.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.